Claims study finds only 31% of adults persist on GLP-1s for a year

The wire

1. 01In 2021-2023 MarketScan data, adult trajectories were immediate discontinuers 19.6%, early 23.5%, late 20.7%, intermittent 5.5% and persistent users 30.7%, with mean annual proportion of days covered from 0.10 to 0.87.
2. 02Prescribers and telehealth operators get a benchmark for real-world attrition in non-diabetic obesity treatment, including 1,139 paediatric patients aged 10 and older.
3. 03Claims data cannot capture reasons for stopping such as cost, shortages or side effects; regional differences, with Northeast odds ratios of 1.32 in adults and 1.65 in children, remain unexplained.

From the source

Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity

Diabetes, obesity & metabolism · 2026 Sep 17 · Huang W, Kotecha P, Kimmel SE et al.